Johnson & Johnson: AI to Halve Drug Development Time

Johnson & Johnson (J&J) anticipates that artificial intelligence (AI) technology will significantly accelerate the drug development process. The company stated that using AI could halve the time required to identify new drug candidates. This development holds potential for increased efficiency and cost savings in the pharmaceutical industry. J&J executives emphasize that AI will revolutionize research and development (R&D) stages. Drug target discovery and optimization processes, which can take months with traditional methods, could be reduced to weeks thanks to AI algorithms. This could enhance the company's ability to expand its drug portfolio and speed up time-to-market. The company believes that AI integration will not only save time but also enable the development of more targeted and effective drugs. J&J views this technology as a strategic tool to increase clinical trial success rates and lower R&D costs. In the long term, AI-driven processes are expected to strengthen the company's competitive advantage. This is not investment advice.